AEON Biopharma, Inc.
AEON- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001837607
In the last 90 days, AEON Biopharma, Inc. insiders filed 1 open-market purchase and 0 sales; 22 institutions reported holding it in 13F filings for Q2 2026, worth $9.22M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in AEON Biopharma, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +7 vs. Q4 2023
- Shares held
- 9.47M
- +805.8K (+9.3%) vs. Q4 2023
- Total value
- $103.5M
- +$46.7M (+82.2%) vs. Q4 2023
- New holders
- 8
- 11 more added
- Sold out
- 1
- 3 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AEON on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $9.22M |
| Q1 2026 | 24 | $2.80M |
| Q4 2025 | 22 | $1.67M |
| Q3 2025 | 21 | $1.10M |
| Q2 2025 | 18 | $585.7K |
| Q1 2025 | 16 | $884.8K |
| Q4 2024 | 37 | $4.80M |
| Q3 2024 | 30 | $10.1M |
| Q2 2024 | 25 | $8.73M |
| Q1 2024 | 27 | $103.5M |
| Q4 2023 | 20 | $56.8M |
| Q3 2023 | 16 | $29.3M |
| Q2 2023 | 17 | $12.0M |
| Q1 2023 | 21 | $19.6M |
| Q4 2022 | 86 | $248.3M |
| Q3 2022 | 81 | $226.5M |
| Q2 2022 | 73 | $213.1M |
| Q1 2022 | 71 | $202.3M |
| Q4 2021 | 73 | $192.0M |
| Q3 2021 | 59 | $171.8M |
| Q2 2021 | 47 | $126.0M |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding AEON Biopharma, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 3,675,000 | $42.6M | 1.14% | −200,000−5.2% | Reduced |
| Atalaya Capital Management LP | 3,675,000 | $36.2M | 42.59% | 00.0% | Unchanged |
| Vanguard Group Inc | 758,992 | $8.80M | 0.00% | +549,207+261.8% | Added |
| Ikarian Capital, LLC | 257,977 | $2.99M | 0.81% | 00.0% | Unchanged |
| BlackRock Inc. | 255,423 | $2.96M | 0.00% | +8,335+3.4% | Added |
| Geode Capital Management, LLC | 179,595 | $2.08M | 0.00% | +7,349+4.3% | Added |
| Goldman Sachs Group Inc | 169,158 | $1.96M | 0.00% | +150,615+812.2% | Added |
| Formidable Asset Management, LLC | 68,193 | $791.0K | 0.13% | +10,000+17.2% | Added |
| Qube Research & Technologies Ltd | 59,815 | $693.9K | 0.00% | +55,891+1,424.3% | Added |
| State Street Corp | 59,550 | $690.8K | 0.00% | +49,500+492.5% | Added |
| Millennium Management LLC | 55,987 | $649.4K | 0.00% | +55,987 | New |
| Boothbay Fund Management, LLC | 55,062 | $638.7K | 0.02% | 00.0% | Unchanged |
| Northern Trust Corp | 48,813 | $566.2K | 0.00% | −1,006−2.0% | Reduced |
| Jane Street Group, LLC | 36,250 | $420.5K | 0.00% | +36,250 | New |
| JPMorgan Chase & Co | 28,498 | $330.6K | 0.00% | +21,609+313.7% | Added |
| Bank of America Corp | 22,995 | $266.7K | 0.00% | −358−1.5% | Reduced |
| Shaolin Capital Management LLC | 21,380 | $248.0K | 0.01% | +21,380 | New |
| Royal Bank of Canada | 14,400 | $167.0K | 0.00% | +14,400 | New |
| Morgan Stanley | 10,404 | $120.7K | 0.00% | +8,604+478.0% | Added |
| Y-Intercept (Hong Kong) Ltd | 10,001 | $116.0K | 0.01% | +10,001 | New |
| LMR Partners LLP | 6,608 | $76.7K | 0.00% | +6,608 | New |
| GHP Investment Advisors, Inc. | 1,095 | $12.7K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 967 | $11.2K | 0.00% | +868+876.8% | Added |
| Catalyst Funds Management Pty Ltd | 285 | $3.31K | 0.00% | +285 | New |
| Wells Fargo & Company | 139 | $1.61K | 0.00% | +2+1.5% | Added |
| DuPont Capital Management Corp | 3 | $35 | 0.00% | 00.0% | Unchanged |
| Macquarie Group Ltd | 901 | $10 | 0.00% | +901 | New |
| UBS Group AG | 0 | $0 | 0.00% | −649−100.0% | Sold out |